Post Marketing Surveillance Study to Observe Safety and Effectiveness of CRYSVITA® in S. Korean Patients

NCT06202027 · clinicaltrials.gov ↗

RECRUITING

Status

100

Enrollment

INDUSTRY

Sponsor class

Conditions

FGF23-related Hypophosphataemic Rickets and Osteomalacia

Interventions

DRUG: FGF23-related hypophosphataemic rickets and osteomalacia

Sponsor

Kyowa Kirin Korea Co., Ltd.